Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 6, 2000, Pages 709-714

  Katz, P O ^a   Hatlebakk, J G ^a   Castell, D O ^a  

^a GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN EXPERIMENT; MALE; NIGHT; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; TREATMENT OUTCOME;

EID: 0034038545     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00775.x     Document Type: Article

References (23)

1. 1 Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastroesophageal reflux disease. Gut 1992; 33: 118-24.
2. 2 Hatlebakk JG, Katz PO, Castell DO. Medical therapy: Management of the refractory patient. Gastroenterol Clin North Am 1999; 4: 847-60.
3. 3 Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
4. 4 Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
5. 5 Castell DO, Castell JA, eds. Esophageal Motility Testing, 2nd edn. Norwalk: Appleton & Lange. 1994: 32-3.
6. 6 Castell JA. Esophageal manometry. In: Castell DO, ed. The Esophagus, 2nd edn. Boston: Little, Brown and Company, 1995: 133-52.
7. 7 Bate CM, Crowe JP, Dickinson RJ, et al. Reflux oesophagitis resolves more rapidly with omeprazole 20 mg once daily than with ranitidine 150 mg twice daily: Omeprazole 40 mg once daily provides further benefit in unresponsive patients. Br J Clin Res 1991; 2: 133-48.
8. 8 Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: Effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 1532-8.
9. 9 Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-40.
10. 10 Cillufo T, Armstrong D, Castiglione F, et al. Reproducibility of ambulatory gastric pH recording in the corpus and antrum. Effect of food, time, and electrode position. Scand J Gastroenterol 1990; 25: 1076-83.
11. 11 Seensalu R, Iwarzon M, Janczewska I, Hammarlund B, Oksanen A, Sagar M. Dose-response comparison of lansoprazole on 24-hour gastric acidity and plasma gastrin in healthy volunteers. Gastroenterology 1995; 108: A215(Abstract).
12. 12 Timmer W, Ripke H, Kleist P, et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Meth Find Exp Clin Pharmacol 1995; 17: 489-95.
13. 13 Blum RA, Vermeire GD, Shi H, et al. Gastric pH levels with lansoprazole 15 mg and 30 mg qd, omeprazole 20 mg qd, and ranitidine 150 mg qd, and ranitidine 150 mg qid. Gastroenterology 1997; 112: A73(Abstract).
14. 14 Tolman KG, Sanders SW, Buchi KN, Karol MD. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70.
15. 15 Sanders SW, Tolman KG, Greski PA, Jennings DE, Hoyos PA, Page JG. The effect of lansoprazole, a new H+, K+ ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992; 6: 359-72.
16. 16 Hatlebakk JG, Katz PO, Castell DO. Proton pump inhibitors should be taken with meals for optimal control of gastric acidity. Gastroenterology 1998; 114: A144-5.
17. 17 Delhotal-Landes B, Cournot A, Vermerie N, Benoit M, Dellatolas F, Flouvat B. The effect of antacid and food on the bioavailability of lansoprazole in man. Eur J Drug Metab Pharmacokinet 1990; 15(Suppl.): 6.
18. 18 Verdu EF, Fraser R, Armstrong D, Blum AL. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori positive volunteers. Scand J Gastroenterol 1994; 29: 1065-9.
19. 19 Katz PO, Silman J, Katzka D, et al. H. pylori (HP) infection increases nocturnal acid control on proton pump inhibitors (PPI). Am J Gastroenterol 1998; 93: 1641.
20. 20 van Herwaarden MA, van Samson M, Nispen CH, Mulder PG, Smout AJ. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13: 731-10.
21. 21 Barclay ML, Begg EJ, Robson RA, Peters WA, Ketelby JW. The pharmacokinetics of lansoprazole in normal volunteers and patients with reflux oesophagitis. Clin Exp Pharmacolo Physiol 1993; 3(Suppl.): 3.
22. 22 Leite LP, Johnson BT, Just RF, Castell DO. Persistent acid secretion during omeprazole therapy; a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 1527-31.
23. 23 Paoletti V, Karvois D, Greski-Rose P, et al. Lansoprazole superior to omeprazole in increasing both 24-hour and nighttime intragastric pH in 'omeprazole failure' GERD patients. Am J Gastroenterol 1997; 92: 1621 (Abstract).